Lung Cancer: Stages and Types of Cells

Lung cancer involves abnormal cell growth in the lungs, making it a complex disease. It is one of the leading causes of cancer-related deaths worldwide. Understanding the different types of lung cancer cells and the stages of the disease is crucial for diagnosis, treatment planning, and prognosis.

Types of lung cancer cells

There are two primary types of lung cancer based on the type of cells affected: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

NSCLC

Non-small cell lung cancer is the most common type, accounting for approximately 85% of all lung cancer cases. NSCLC can be divided into several subtypes based on the specific type of lung cells that are affected:

• Adenocarcinoma: This is the most common subtype of NSCLC, often found in the outer regions of the lungs. It is frequently seen in non-smokers and tends to grow slower than other types.

• Squamous cell carcinoma: This type typically arises in the larger airways of the lungs. It is strongly associated with a history of smoking and may be linked to chronic lung diseases like COPD (chronic obstructive pulmonary disease).

• Large cell carcinoma: This subtype is less common and can appear in any part of the lung. It tends to grow and spread quickly.

SCLC

Small cell lung cancer accounts for about 10-15% of lung cancer cases. Unlike NSCLC, SCLC is more aggressive and tends to spread rapidly to other parts of the body. This type of cancer is strongly associated with smoking.

Stages of lung cancer: TNM system

The TNM staging system determines the stages of lung cancer by evaluating the size of the primary tumor (T), assessing whether cancer has spread to nearby lymph nodes (N), and determining if cancer has metastasized to distant organs (M).

T (Tumor)

• TX: The primary tumor cannot be assessed.

• T0: No evidence of primary tumor.

• T1, T2, T3, T4: Increasing size and/or extent of the primary tumor.

N (Node)

• NX: The regional lymph nodes cannot be assessed.

• N0: No regional lymph node involvement.

• N1, N2, N3: Increasing involvement of regional lymph nodes.

M (Metastasis)

• MX: The presence of distant metastasis cannot be assessed.

• M0: No distant metastasis.

• M1: Distant metastasis present.

Stages of non-small cell lung cancer (NSCLC)

Staging of NSCLC categorizes the disease into several categories based on the extent of tumor spread:

Occult-stage NSCLC

• Cancer cells are found in sputum or bronchial washing, but no tumor is visible on imaging.

Stage 0 non-small cell lung cancer

• Cancer cells are present only in the lining of the lung and have not invaded deeper lung tissue.

Stage 1 non-small cell lung cancer

• Cancer is limited to the lung and has not spread to lymph nodes or other organs.

Stage 2 non-small cell lung cancer

• Cancer has spread to nearby lymph nodes or invaded nearby structures such as the chest wall or diaphragm.

Stage 3 non-small cell lung cancer

• Cancer has spread to lymph nodes in the mediastinum (center of the chest) or to nearby structures such as the heart or esophagus.

Stage 4 non-small cell lung cancer

• Cancer has spread to distant parts of the body, such as the liver, bones, or brain.

Stages of small cell lung cancer (SCLC)

Typically, clinicians categorize SCLC into two main stages:

Limited-stage small cell lung cancer

• Cancer confines itself to one side of the chest and may involve nearby lymph nodes.

Extensive-stage small cell lung cancer

• Cancer has spread extensively beyond the lung to distant organs and lymph nodes.

Understanding lung cancer type and stage is crucial for treatment selection, including surgery, chemotherapy, radiation, targeted therapy, immunotherapy, or a combination. Early screening is key to better outcomes.

Innovative methods like Altum Sequencing offer promising ways to manage lung cancer. Altum Sequencing specializes in liquid biopsy, particularly in minimal residual disease (MRD) monitoring.

Altum Sequencing tracks genetic signatures of circulating cancer cells, allowing precise monitoring of disease progression or recurrence. By detecting specific genetic mutations, Altum Sequencing helps tailor treatment plans and assess effectiveness.

Following cancer’s genetic trail through liquid biopsy has great potential to improve care and outcomes. Technologies like Altum Sequencing enable personalized, targeted therapies based on each patient’s tumor profile, reducing unnecessary interventions and recurrence risk.

These advancements in technology hold promise for more effective and personalized lung cancer treatments, aiming to enhance patient outcomes and quality of life.